Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Topical bevacizumab may inhibit corneal neovascularization

Poster Details

First Author: M.Mirdehghan IRAN

Co Author(s): A. Kasiri   H. Hedayati   M. Montazeri   S. Emadi   N. Kasiri        

Abstract Details


To evaluate the effect of topical bevacizumab on corneal neovascularization (CNV) in rabbit model following corneal injury.


Experimental study at Ahvaz University of Medical Sciences


Corneal neovascularization induced by 3 sutures of the cornea in 20 rabbits (20 corneas). Two weeks later all sutures removed and subsequently rabbits were divided randomly into two groups: first group received topical bevacizumab at 10 mg/mL and the second one received only topical normal salin drops as the control group three times a day for two weeks. Photographs of CNV obtained prior medication administration and at 1 and 2 weeks after therapy. The images were analyzed using NIH Imagej 1.49c software.


The mean percentage of CNV area estimated as 100 % prior to treatment. One week after treatment the mean percentage of neovascularization area in Bevacizumab and Salin group were 75.64±4.32 and 93.33±4.57 respectively. Furthermore at the 2 week after treatment it was 61.45±6.18 and 84.96±5.21 respectively. The neovascularization area in Bevacizumab group regressed in comparison with salin group significantly (P<0.0001).


Topical administration of Bevacizumab reduces corneal neovascularization in the short term period, therefore it can be applied in corneal neovascularization.

Financial Disclosure:


Back to Poster listing